Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Gleevec in Late Chronic Phase CML
NCT01092741Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2001
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in chronic myeloid leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2001; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01092741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01092741.